Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CXCL10 mRNA lipid nanoparticles
- Development stage
- Preclinical
- Lead developer
- Peking University Cancer Hospital & Institute
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Inhalation
01
Overview
CXCL10 mRNA lipid nanoparticles is a preclinical-stage, lung-targeted mRNA therapeutic formulated in lipid nanoparticles (LNPs) containing 10% DOTAP. Developed by Peking University Cancer Hospital and the Institute of Zoology, Chinese Academy of Sciences, it is designed for nebulized pulmonary delivery to treat lung cancer. By delivering mRNA encoding C-X-C motif chemokine ligand 10 (CXCL10), the therapy reconstitutes a lung-restricted chemokine gradient in the tumor microenvironment. This gradient enhances the recruitment of CXCR3-expressing chimeric antigen receptor (CAR) T cells (such as B7H3- or mesothelin-targeted CAR-T cells) to the lungs, improving their trafficking, infiltration, and antitumor efficacy while reducing systemic toxicity.
- Other names
- CXCL10 mRNA lipid nanoparticleCXCL-10 mRNA lipid nanoparticleCXCL 10 mRNA lipid nanoparticleCXCL10 mRNA-LNPCXCL-10 mRNA-LNPCXCL 10 mRNA-LNPnebulized CXCL10 mRNA-LNPs
02
Targets
CXCL10 (C-X-C Motif Chemokine Ligand 10)CCR3 (C-C chemokine receptor type 3)TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on CXCL10 mRNA lipid nanoparticles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CXCL10 mRNA lipid nanoparticles.